Not So Fast, I’m Serofast: Using Innovative Education Techniques to Drive Management of People with Syphilis - Kan, Dennis; Stenzel, Molly; Thompson, Julie; De Gagne, Jennie; McGee, Kara (medRxiv, 2025)
Background An increase in syphilis cases in the United States and the global shortage of Benzathine Penicillin G (BPG) calls for evidence-based optimization. Confusing serologies and incomplete sexual history exacerbate the overprescription of BPG, especially for patients with “serofast” serologies. Seronegative status develops through natural decline and not through additional therapy.Method A longitudinal pre-post design was implemented within a health maintenance organization serving Oregon and Southwest Washington. Interventions included microlearning education, allowing quick access to clinical recommendations and actionable patient education empowers patients.Results BPG was administered 187 times (69 pre-intervention, 118 post-intervention), and inappropriate administration showed a 7.9% relative decline (10.1% to 9.3%). There was no difference in outcomes between the newly infected and reinfected patients. Patient education utilization increased from 4.3% to 6.8%, representing a 58.1% relative improvement. Clinician microlearning utilization decreased by 25.3% during the post-intervention period.Conclusion This project demonstrated modest improvements in the administration of appropriate BPG and utilization of patient education, although the results did not reach statistical significance. Future interventions should focus on automating patient education and enhancing the visibility of clinical resources. This project highlighted the importance of obtaining patients’ treatment histories and recent exposure risks. The increasing prevalence of syphilis among women who have sex with men (WSM) represents an epidemiological shift with implications for maternal-child health. The growing prevalence of syphilis among non-traditional risk groups emphasizes the importance of comprehensive sexual health screening approaches to mitigate adverse outcomes.What is already known on this topic Syphilis is a sexually transmitted infection (STI) with public health urgency and a global impact due to shortage and emergence. There are studies on the effects of syphilis and public health, but they do not address how to combat the syphilis epidemic. A common practice is that many medical providers are not familiar with how to interpret syphilis results, which can lead to overtreatment of patients, especially those who are serofast. There are also limited studies that look at the feasibility and utilization of using education to lower syphilis rates.What this study adds From this study, we found that using innovative educational methods, microlearning, and patient-centered patient education can modestly reduce the inappropriate treatment of syphilis. Syphilis treatment is complex, and knowledge gaps that exist include too frequent testing and not obtaining an adequate sexual health history. This study also confirms that there is an importance of screening other populations and not just men who have sex with men (MSM).How might this study affect research, practice, or policy?This study shows the urgency of the treatment shortage and the rising rate of syphilis, calling for an innovative approach. Institutions need to look at other ways to address the syphilis epidemic, such as utilizing practical tools from this study to decrease the inappropriate use of syphilis treatment. These interventions are helpful for medical providers and provide patients with a means to advocate for their health. Refocusing on the clinical need of appropriate history taking in conjunction with serologies to properly treat people with syphilis. Other innovation measures, such as microlearning videos and artificial intelligence, can be tools to aid in appropriate syphilis treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Kaiser Permanente Interregional IRB (KPiIRB) Office determined that this project did not meet the regulatory definition of research and did not involve human subjects.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript